Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > ensituximab
ensituximab
Thursday 14 April 2016
| WP |
Ensituximab is designed against the mucin epitope NPC-1C in pancreatic and colon cancer.
Ensituximab is a chimeric monoclonal antibody used in the treatment of cancers. Ensituximab was developed by Neogenix Oncology, Inc.
Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) without contributing significant toxicity, according to findings from a phase II study reported at the 2016 Gastrointestinal Cancers Symposium.
References
http://www.targetedonc.com/news/ensituximab-proves-promising-in-refractory-mcrc#sthash.rq0A7W0j.dpuf